Literature DB >> 24708193

Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures.

Marco Picardi1, Novella Pugliese, Michele Cirillo, Pio Zeppa, Imma Cozzolino, Giuseppe Ciancia, Guido Pettinato, Claudia Salvatore, Concetta Quintarelli, Fabrizio Pane.   

Abstract

PURPOSE: To compare the use of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) with the use of a combination of ultrasonography (US) and chest radiography for systematic follow-up of patients with high-risk Hodgkin lymphoma.
MATERIALS AND METHODS: Institutional review board approval and informed consent were obtained. In a single center between January 2001 and December 2009, patients with advanced-stage Hodgkin lymphoma who had responded completely to first-line treatment were randomly assigned (1:1) to follow-up with either PET/CT or US/chest radiography. Follow-up included clinical and imaging procedures at 4, 8, 12, 16, 20, 24, 30, 36, 48, 60, 84, and 108 months after treatment discontinuation. When clinical and/or imaging results were positive, recurrence was confirmed histologically. The primary endpoint was to compare the sensitivity of the two follow-up imaging approaches. Secondary endpoints were their specificity, positive and negative predictive values, time to recurrence detection, radiation risks, and costs.
RESULTS: A total of 300 patients were randomized into the two arms. The study was closed after a median follow-up time of 60 months, with a relapse rate of 27%. Sensitivity for detection of Hodgkin lymphoma was similar for the two follow-up approaches. All of the relapses (40 of 40) were identified with FDG PET/CT (100%) and 39 of 40 relapses were identified with US/chest radiography (97.5%; P = .0001 for the equivalence test). US/chest radiography showed significantly higher specificity and positive predictive value than did PET/CT (96% [106 of 110] vs 86% [95 of 110], respectively; P = .02; and 91% [39 of 43] vs 73% [40 of 55], respectively; P = .01). Exposure to ionizing radiation was estimated to be 14.5 mSv for one PET/CT examination versus 0.1 mSv for one chest radiographic examination. Estimated cost per relapse diagnosed with routine PET/CT was 10-fold higher compared with that diagnosed with routine US/chest radiography.
CONCLUSION: US and chest radiography are diagnostic tools that enable effective, safe, and low-cost routine surveillance imaging for patients at high risk of Hodgkin lymphoma relapse. © RSNA, 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24708193     DOI: 10.1148/radiol.14132154

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

Review 1.  Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma.

Authors:  Jonathon B Cohen; Madhusmita Behera; Carrie A Thompson; Christopher R Flowers
Journal:  Blood       Date:  2016-12-12       Impact factor: 22.113

2.  Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.

Authors:  Elizabeth A Mullen; Yueh-Yun Chi; Emily Hibbitts; James R Anderson; Katarina J Steacy; James I Geller; Daniel M Green; Geetika Khanna; Marcio H Malogolowkin; Paul E Grundy; Conrad V Fernandez; Jeffrey S Dome
Journal:  J Clin Oncol       Date:  2018-10-18       Impact factor: 44.544

3.  Evidence-Based Follow-up for Adults With Cancer.

Authors:  Ulrich Dührsen; Karl-Matthias Deppermann; Christian Pox; Axel Holstege
Journal:  Dtsch Arztebl Int       Date:  2019-10-04       Impact factor: 5.594

4.  Cumulative radiation exposure from imaging procedures and associated lifetime cancer risk for patients with lymphoma.

Authors:  Grete Fabritius; Gunnar Brix; Elke Nekolla; Stefan Klein; Henning D Popp; Mathias Meyer; Gerhard Glatting; Claudia Hagelstein; Wolf K Hofmann; Stefan O Schoenberg; Thomas Henzler
Journal:  Sci Rep       Date:  2016-10-17       Impact factor: 4.379

Review 5.  Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy.

Authors:  Hugo J A Adams; Rutger A J Nievelstein; Thomas C Kwee
Journal:  Ann Hematol       Date:  2016-01       Impact factor: 3.673

6.  Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma.

Authors:  Novella Pugliese; M Di Perna; I Cozzolino; G Ciancia; G Pettinato; P Zeppa; V Varone; S Masone; C Cerchione; R Della Pepa; L Simeone; C Giordano; V Martinelli; C Salvatore; F Pane; M Picardi
Journal:  Ann Hematol       Date:  2017-01-27       Impact factor: 3.673

7.  Sulfur Exafluoride Contrast-Enhanced Ultrasound Showing Early Wash-Out of Marked Degree Identifies Lymphoma Invasion of Spleen with Excellent Diagnostic Accuracy: A Monocentric Study of 260 Splenic Nodules.

Authors:  Marco Picardi; Claudia Giordano; Fabio Trastulli; Aldo Leone; Roberta Della Pepa; Novella Pugliese; Rossella Iula; Giuseppe Delle Cave; Maria Gabriella Rascato; Maria Esposito; Elena Vigliar; Giancarlo Troncone; Massimo Mascolo; Daniela Russo; Marcello Persico; Fabrizio Pane
Journal:  Cancers (Basel)       Date:  2022-04-11       Impact factor: 6.575

8.  Follow-up strategies following completion of primary cancer treatment in adult cancer survivors.

Authors:  Beverley L Høeg; Pernille E Bidstrup; Randi V Karlsen; Anne Sofie Friberg; Vanna Albieri; Susanne O Dalton; Lena Saltbæk; Klaus Kaae Andersen; Trine Allerslev Horsboel; Christoffer Johansen
Journal:  Cochrane Database Syst Rev       Date:  2019-11-21

Review 9.  FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma-An Updated Overview.

Authors:  Conrad-Amadeus Voltin; Jasmin Mettler; Jirka Grosse; Markus Dietlein; Christian Baues; Christine Schmitz; Peter Borchmann; Carsten Kobe; Dirk Hellwig
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.